Kornimate/medical-research-clean huggingface dataset:
chemqbiosciences:manual liquid based cytology

Conditions: Cervical Dysplasia; Cervical Cancer

Summary: purpose: to assess equivalence between low cost manual liquid based cytology (pap smear) and standard thin prep cytology screening. participants: 100-120 healthy women presenting for standard pap smear screening procedures (methods): after routine care pap smear, another pap smear will be performed and placed in the study medium. clinical care pap and study pap will be reviewed by a single pathologist to assess for equivalent findings. hypothesis: manual liquid based cytology is equivalent to conventional liquid based cytology.

purpose: to assess equivalence between low cost manual liquid based cytology (pap smear) and standard thin prep cytology screening. participants: 100-120 healthy women presenting for standard pap smear screening procedures (methods): after routine care pap smear, another pap smear will be performed and placed in the study medium. the study pap medium will be processed using the manufacturers instructions and then clinical care pap and study pap will be reviewed by a single pathologist to assess for equivalent findings.

Eligibility criteria:
inclusion criteria: * female ages 18 years or older * english speaking * presenting for pap smear examination exclusion criteria: * pregnancy

Keywords: cervical dysplasia cervical cancer
tomo versus imrt in nasopharyngeal carcinoma patients

Conditions: Nasopharyngeal Carcinoma

Summary: tomotherapy is a new radiation planning and delivery technology which may allow for delivery of higher radiation doses with less damage to normal tissues. the investigators aim to compare the treatment efficacy and quality of life between tomotherapy and intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma


Eligibility criteria:
inclusion criteria: 1. patients with newly histologically confirmed non-keratinizing carcinoma. 2. tumor staged t1-4n0-3m0 （according to the 8th ajcc staging system） 3. performance status: kps\>70 4. with normal liver function test (alt, ast \<1.5uln) 5. renal: creatinine clearance \>60ml/min 6. without hematopathy,marrow: wbc \>4\*109/l, hgb\>80g/l, and plt\>100\*109/l. 7. written informed consent exclusion criteria: 1. who type i squamous cell carcinoma or adenocarcinoma 2. age \>65 or \<18 3. prior malignancy (except adequately treated carcinoma in-situ of the cervix or basal/squamous cell carcinoma of the skin) 4. previous chemotherapy or radiotherapy (except non-melanomatous skin cancers outside the intended rt treatment volume) 5. patient is pregnant or lactating 6. any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose \>1.5×uln), and emotional disturbance. -
navigating the clinical research process for mild cognitive impairment

Conditions: Mild Cognitive Impairment

Summary: participation in medical research usually favors a particular demographic group. but there is limited research available to explain what trial attributes affect the completion of these specific demographic groups. this trial will admit a wide range of data on the clinical trial experience of mild cognitive impairment patients to determine which factors prevail in limiting a patient's ability to join or finish a trial. it will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future mild cognitive impairment patients.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of mild cognitive impairment * participant must be 18 years of age or older * participant must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, and other requirements of the study. exclusion criteria: * pregnant or lactating woman * participant is actively receiving study therapy in another * inability to provide written informed consent

Keywords: mild cognitive impairment
inhibitory effect of a polyphenol supplement on dietary iron absorption in adults with thalassemia

Conditions: Thalassemia; Iron Overload

Summary: genetic disorders, such as thalassemia, can lead to iron overload and severe adverse health outcomes. in iron-loading thalassemia, iron overload is due to increased iron absorption. iron accumulates in the body organs causing widespread damage. the standard treatment is iron chelation therapy and/or periodic phlebotomy to remove iron from the body; frequency of phlebotomy or chelation therapy is dependent on how quickly body iron stores accumulate. polyphenolic compounds are very strong inhibitors of non-heme iron absorption, as they form insoluble complexes with ferrous iron in the gastrointestinal tract that cannot be absorbed. the investigators have recently shown in european subjects with hereditary hemochromatosis (another iron-loading disorder) that our newly-developed natural polyphenol supplement (pps) that is rich in polyphenols, when taken with iron-rich meals or with an iron-fortified drink, reduces iron absorption by \~40%. decreasing non-heme iron absorption in adults with iron-loading thalassemia could potentially lead to an extension of the time period between phlebotomies or chelation therapies, and therefore an improved quality of life. therefore, in this stable iron isotope study, the investigators will study the effect the natural pps on oral iron absorption from an iron-rich test meal or iron-fortified drink in thai adults with iron-loading thalassemia.


Eligibility criteria:
inclusion criteria: * documented diagnosis of thalassemia minor or intermedia (β-thalassemia with or without α-globin gene mutations, hb e/β-thalassemia with or without α-globin gene mutations, or α-thalassemia hb h disease) based on hb electrophoresis/hplc and/or dna analysis from the subject's medical record. * hemoglobin (hb): 7.0-13.5 g/dl for males; 7.0-12.0 for females * serum ferritin (sf): 300-800 ug/l for males; 200-800 ug/l for females * not having had a blood transfusion within 6 months prior to the study start * age 18-49 y, not pregnant or lactating * body weight \<75 kg and body mass index (bmi) between 17 and 25 kg/m2 * no acute illness/infection (self-reported) * no metabolic or gastrointestinal disorders, eating disorders or food allergy to the ingredients of the test meal (self-reported) * no scheduled phlebotomy or blood transfusion during the study period * the last phlebotomy will be at least 4 weeks prior to first study visit * no intake of iron chelators 4 weeks prior to first study visit and throughout the study period * no use of medications affecting iron absorption or metabolism during the study * no intake of mineral/vitamin supplements 2 weeks prior to the first study visit and during the study * no participation in any other clinical study within the last 30 days and during the study * expected to comply with study protocol

Keywords: iron overload thalassemia polyphenols iron absorption
effect of proprioceptive neuromuscular facilitation techniques on elderly people with scapular disposition

Conditions: Geriatric Rehabilitation; Scapular Dyskinesis

Summary: proprioceptive neuromuscular facilitation (pnf) has been defined as a comprehensive rehabilitation approach focusing on a motor learning effect, especially in the elderly. therefore, pnf can be an effective treatment method for our purpose which is to analyze if pnf techniques improve balance and gait characteristics in elderly with scapular disposition and to determine the difference when used with the gait education

participants will be randomly divided into 2 groups. scapular pnf techniques in addition to gait training will be applied to the 1st group for 8 weeks, and only gait training exercises will be applied to the 2nd group for 8 weeks. individuals will be evaluated in detail at the beginning, and end of the study, and after 3 months as a follow-up evaluation. for the assessment of scapular disposition, the visual scapular disposition test and lateral scapular slide test will be applied. walking speed will be evaluated with a dedicated area by measuring the distance. the modified dynamic gait index will be used for measuring the ability of the participant to maintain walking balance while responding to different task demands. for fall risks and functional mobility timed up and go test and falls efficacy scale will be used. for balance assessment berg balance scale and functional reach test. for assessment of the quality of life, sf-36 will be used. posture will be assessed with a dedicated application called postureco

Eligibility criteria:
inclusion criteria: * having scapular disposition (patients will be determined after the visual scapular disposition test and lateral scapular slide test) * with no injuries * able to walk without any assistive devices * to be able to read and write in turkish exclusion criteria: * having a musculoskeletal or neurological problem that causes issues with applying the intervention. * any orthopedic, neurological, cardiac, vestibular, visual, or psychiatric impairment which would not allow them to perform * had physiotherapy during the past 3 months

Keywords: geriatric rehabilitation scapular disposition balance posture gait
360 degrees virtual reality-based mirror therapy for stroke patients

Conditions: Stroke; Stroke Rehabilitation; Mirror Movement Therapy

Summary: the goal of this randomized controlled trial is to compare the effects of 360 degree virtual reality-based mirror therapy (360mt) to traditional mirror therapy (tmt) and conventional physical therapy (control group) on upper extremity function among stroke patients. the main questions it aims to answer are: * would 360mt be more effective when treated for 4 weeks in outcome measure ments including: fugl-meyer assessment for upper extremity (fma-ue); manual function test (mft); and box \& block test (bbt)? * how would particants' experience be in terms of satisfactory and enjoyment during 360mt? the study will have three groups of participants who will be involved in different tasks: * 360mt group: will receive mirror therapy using a virtual reality device (hmd) and perform tasks with their paralyzed hand. sessions will last 30 minutes, 3 times a week for 4 weeks. * tmt group: will receive mirror therapy using an acrylic mirror and perform finger, wrist, elbow exercises using their paralyzed limb. sessions will last 30 minutes, 3 times a week for 4 weeks. * control group: will receive conventional physical therapy consisting of exercises for the upper extremity, 60 minutes per day, 5 sessions a week, for 4 weeks.


Eligibility criteria:
inclusion criteria: * who have not passed 12 months since onset; * who can understand and follow instructions; * who have ≥21 scores in korean version of mini-mental state examination (mmse-k); * who have mild to moderate motor impairment according to the fugl meyer assessment (fma) scores exclusion criteria: * patients who have any kinds of mental disorder and/or alzheimer's disease; * who have orthopedic and/or musculoskeletal injury; * who have apraxia; and * who have previous experiences of participating in investigations and/or mirror therapy.

Keywords: stroke stroke rehabilitation mirror movement therapy
modified myocardial performance index and epicardial thickness in cases with idiopathic polyhydramnios

Conditions: Fetal Diagnose; Fetal Cardiac Disorder

Summary: in cases diagnosed as idiopathic polyhydramnios and healthy pregnancy between 24-40 weeks (total number of cases (100-120)), prospective fetal echocardiography will be performed to evaluate mpi and eft.

: gestational week, maternal age, amniotic fluid index measurement, modified myocardial performance in fetal echo and epicardial thickness of all cases will be evaluated. week of pregnancy, body mass index, fetal biometry, umbilical artery doppler, middle cerebral artery doppler measurements will be taken. birth weight and fetal intensive care hospitalizations at the birth week of all cases will be recorded. all data will be evaluated with the appropriate statistical method.

Eligibility criteria:
inclusion criteria: 24-40 weeks gestational age, polyhydramnios and healthy pregnancy - exclusion criteria: multıpl pregnancy, fetal anomaly, growth restriction, maternal chronic disease -

Keywords: polyhidramnios, epicard, myocardial performance index
smoking prevention program in poland

Conditions: Smoking; Smoking Behaviors; Smoking (Tobacco) Addiction; E-cigarette Use; Vaping

Summary: smoking prevention program is a pilot exploratory study with a standardized curriculum based on the tobacco prevention toolkit from stanford university and translated into polish by the members of students scientific association of oncology at wroclaw medical university. the program will assess the effectiveness of a school-based smoking prevention curricula keeping children as never smokers and test the feasibility of engaging medical students and teachers in implementing and evaluating a validated program on smoking prevention within the polish school system. the research protocols, methods and data collection instruments of a standardized classroom based valid tobacco prevention program from stanford university will be used for the study. the smoking prevention program is centred on drug resistance, personal self-management and increasing social skills. the program increases knowledge and uses coaching and practice to provide students with the skills to resist social pressures around cigarette use. the secondary outcome of this study is to determine the change in attitudes by polish medical student regarding cancer prevention research. during smoking prevention program workshops, the 5-session curriculum for primary schools will be translated, applied and evaluated for polish students. this community-based pilot will engage medical students, the local school district and the local health authority. the educational program meets the requirements set by centers for disease control and prevention (cdc) in guidelines for school health programs to prevent tobacco use and addiction. following parental consent, the program will be implemented with all 7th and 8th grade students (children age 12-15 years) from the elementary school in tyniec mały. this project is supported by the head of lower silesian oncology center, the head of department of oncology of wroclaw medical university, the health and social affairs department of city of wroclaw and under the patronage of the lower silesia governor's office, the polish society of oncology, the polish society of public health, the lower silesian department of polish society of cardiology and the european association for cancer education (eace). smoking prevention program is funded by the reads grant program from the american association for cancer education (aace).


Eligibility criteria:
inclusion criteria: * students from tyniec mały * 7th and 8th graders of the elementary school * parental consent * students consent exclusion criteria: * lack of parental consent * lack of students consent

Keywords: tobacco prevention cancer smoking prevention cancer education educational intervention cardiovascular diseases prevention youth
short segment vs long segment fixation in traumatic dorsolumbar spine fractures

Conditions: SPINAL Fracture

Summary: a prospective study included 91 patients, who had single level thoracolumbar fracture with cobb's angle ≤ 25⁰, underwent posterior fixation. forty four patients underwent short segment fixation with screws into the index level, and 47 patients underwent long segment fixation with skipped index level. the angle of correction, pain, and neurological state were regularly assessed


Eligibility criteria:
inclusion criteria: * wedge fracture or burst fracture with thoraco-lumbar injury classification and severity (tlics) score ≥ 4 * single level fracture * less than 50% of spinal canal compromised * mild kyphosis or scoliosis * cobb's angle ≤ 25˚ * with or without neurological deficit exclusion criteria: * patients with multiple level fractures * patients with more than 50% spinal canal compromise * patients who needed anterior approach to decompress the canal * patients who have fracture dislocation and / or marked kyphosis and scoliosis with cobb's angle \>25⁰ * patients who needed 360⁰ fixation with long segment fixation to maintain the angle of correction.

Keywords: thoracolumbar fracture short segment fixation long segment fixation index level
prevalence of severe asthma in spanish hospitals

Conditions: Asthma

Summary: asthma is a chronic disease. prevalence of asthma in 2014 among spanish population was 5%, of which 10% were diagnosed with severe asthma. according to spanish national guideline for the management of asthma (gema) 4.1 criteria, asthma can be classified according to its severity (intermittent, mild persistent, moderate persistent or severe persistent) or level of asthma control (controlled, partly controlled or uncontrolled). this guideline describes that only 1 in 10 subjects with severe asthma is well controlled, meaning that there is a 90% prevalence of non-controlled severe asthma. this prospective, non-interventional, observational, multicenter and case-control study aims to assess the prevalence of severe asthma in spanish hospitals. the study will describe the characteristics of severe versus non-severe asthmatic subjects, assess their eligibility to receive biological treatments approved for this disease, resource consumption and evaluate the most prevalent phenotypes of severe asthma in spain. enrolled subjects will be divided into two cohorts, based on asthma severity according to the global initiative for asthma (gina) and the international european respiratory society (ers)/american thoracic society (ats) guidelines. cohort a: subjects diagnosed of severe asthma and cohort b: subjects with non-severe asthma. approximately 320 severe asthmatic subjects and 160 non-severe asthmatic subjects will be enrolled in the study. a software of big data will be used to do a sub study for comparing the results obtained through this software tool against results obtained through gold standard classical methods used in this prospective observational study (the descriptive assessment of severe asthma prevalence and the prospective evolution of subjects).


Eligibility criteria:
inclusion criteria * group a: subjects with severe asthma can be enrolled, when they fulfill the following criteria: * subjects \>= 18 years * subjects diagnosed with "severe asthma" defined as asthma that requires high-dose inhaled corticosteroids (ics) plus long-acting beta2-agonist (laba), leukotriene modifier/ theophylline in the last 12 months or continuous/almost continuous treatment with systemic glucocorticosteroids (cs) for \>= 50% of the previous year to maintain control of asthma * subjects treated with ics/laba, with the maximum dose recommended by specific product characteristics (spc). * subjects who give voluntary written informed consent after explanation of study´s procedures. * group b: subjects with non-severe asthma can be enrolled, when they fulfill the following criteria: * subjects \>= 18 years * subjects diagnosed with non-severe asthma per gina guidelines classification * subjects who give voluntary written informed consent after explanation of study´s procedures exclusion criteria * subjects who are not able to complete all the follow-ups of the study with all the study procedures

Keywords: gina guidelines prevalence mepolizumab severe asthma spain
safety and efficacy of avp-923 in pba patients with als or ms

Conditions: Pseudobulbar Affect (PBA)

Summary: objectives of the study are to evaluate the safety, tolerability, and efficacy of two different doses of avp-923 (capsules containing either 30 mg of dextromethorphan hydrobromide and 10 mg of quinidine sulfate \[avp-923-30\] or 20 mg of dextromethorphan hydrobromide and 10 mg of quinidine sulfate \[avp-923-20\]) when compared to placebo, for the treatment of pba in a population of patients with amyotrophic lateral sclerosis (als) or multiple sclerosis (ms) over a 12-week period. an additional objective is to determine the pharmacokinetic parameters of the two different doses of avp-923 in a subset of the study population. pseudobulbar affect (pba) is a condition characterized by involuntary, sudden and frequent episodes of laughing and/or crying out of proportion or incongruous to the underlying emotion of happiness or sadness other terms used to describe this condition include emotional lability, emotionalism, emotional incontinence, emotional discontrol, excessive emotionalism, and pathological laughing and crying. the outbursts can occur spontaneously or in response to provocative stimuli such as questions or events. a body of evidence suggests that pba can be modulated through pharmacologic intervention. dextromethorphan (dm) is a low-affinity uncompetitive antagonist of the n-methyl-d-aspartate (nmda) receptor, reducing the level of excitatory activity. dm also acts at the phencyclidine-binding site, which is part of the nmda receptor complex. dm is a sigma receptor agonist, suppressing the release of excitatory neurotransmitters. quinidine (q) is a known potent inhibitor of cytochrome p450 2d6 (cyp2d6), that decreases the metabolism of dextromethorphan and helps to achieve sustained and therapeutic levels of this drug.


Eligibility criteria:
main inclusion criteria: * the patient has a diagnosis of amyotrophic lateral sclerosis (according to el escorial criteria, wfn, 1998) and the time from diagnosis of als is not be longer than 30 months, or the patient has a diagnosis of multiple sclerosis or probable multiple sclerosis (according to mcdonald criteria, 2001) * the patient has a clinical history and clinical relevant symptoms of pseudobulbar affect (pba) * cns-ls score at baseline is 13 or greater main exclusion criteria: * patients with myasthenia gravis * any personal history of complete heart block, qtc prolongation, or torsades de pointes * any family history of congenital qt interval prolongation syndrome * patients with known sensitivity to quinidine, dextromethorphan or opiate drugs (codeine, etc.)

Keywords: amyotrophic lateral sclerosis (lou gehrig's disease, als) multiple sclerosis (ms)